Shots:

• The company reported the new data from the P-I COVID-19 trial evaluating the safety & immunogenicity of VXA-CoV2-1 suggesting that vaccine triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins and has broad cross-coronavirus activity
• The results showed higher CD8+ T-cell responses as measured by IFN-g and TNF-a induction than the patients vaccinated with Pfizer and Moderna’s vaccines
• The Vaxart vaccine candidate elicited a T-cell response against SARS-Cov-2- as well as showed cross-reactivity against diverse endemic coronaviruses such as 229E- NL63- HKU1- and OC43

  Ref: GLOBE NEWSWIRE | Image: Vaxart